The improved pharmacokinetic and pharmacodynamic properties of FGF21-164 underscore its therapeutic potential for addressing metabolic disorders, particularly the obesity-associated dysregulation of glucose and lipid metabolism, and nonalcoholic steatohepatitis. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.